News
-
-
-
COMMUNIQUÉ DE PRESSE
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Newron Pharmaceuticals S.p.A. announces positive Phase II/III study results of evenamide in schizophrenia patients, meeting primary and key secondary endpoints with good tolerability -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report
Xlife Sciences AG reports strong portfolio growth and strategic advances in the 2023 Valuation Report by independent consulting firm CYLAD Experts. Portfolio valued at CHF 611.7-747.8 million -
-
-
COMMUNIQUÉ DE PRESSE
Straumann Group showed a solid start into 2024, with varied regional growth dynamic
Straumann Group reports strong organic revenue growth of 15.1% in the first quarter of 2024, reaching CHF 643.8 million. Regional dynamics vary, with Asia Pacific leading. New premium implant system and intraoral scanner launched -